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Abstract 
The cardiac voltage-gated sodium channel (gene: SCN5A, protein: NaV1.5) is responsible for 
the sodium current that initiates the cardiomyocyte action potential. Research into the 
mechanisms of SCN5A gene expression has gained momentum over the last few years. We 
have recently described the transcriptional regulation of SCN5A by GATA4 transcription 
factor. In this addendum to our study, we report our observations that 1) the linker between 
domains I and II (LDI-DII) of NaV1.5 contains a nuclear localisation signal (residues 474-481) 
that is necessary to localise LDI-DII into the nucleus, and 2) nuclear LDI-DII activates the SCN5A 
promoter in gene reporter assays using cardiac-like H9c2 cells. Given that voltage-gated 
sodium channels are known targets of proteases such as calpain, we speculate that NaV1.5 
degradation is signalled to the cell transcriptional machinery via nuclear localisation of LDI-DII 
and subsequent stimulation of the SCN5A promoter.  
 
Introduction 
Voltage-gated sodium channels are vital proteins in cardiac physiology. Upon 
changes in membrane potential, sodium channels open and enable the inward, depolarising 
sodium currents that underlie Phase 0 of the cardiomyocyte action potential.1 NaV1.5, 
encoded by the SCN5A gene, is the pore-forming, α subunit, of the cardiac voltage-gated 
sodium channel, and is necessary and sufficient to generate voltage-dependent, inward 
sodium currents. NaV1.5 is an essential protein and Scn5A -/- mice are not viable, while 
Scn5A +/- knockout mice display cardiac conduction defects and ventricular tachycardia.2  
In humans, genetic variants in SCN5A have been linked to cardiac arrhythmias (atrial 
and ventricular fibrillation), sudden cardiac death syndromes (Brugada syndrome, long QT 
syndrome, sudden infant death syndrome) and other cardiac phenotypes (conduction defects, 
sick sinus syndrome).3 We have recently shown that SCN5A expression is regulated by the 
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GATA4 transcription factor in the human heart.4 Recent evidence suggests that abnormal 
SCN5A gene expression is associated with arrhythmogenic diseases (discussed in Tarradas et 
al. 2017),4 and therefore the understanding of how SCN5A expression is controlled 
constitutes an important step forwards in the field of cardiac diseases related to NaV1.5 
dysfunction. 
NaV1.5 is a large (2016 residues, ca. 220 KDa), hydrophobic, integral membrane 
protein that consists of four homologous domains (termed DI to DIV), joined by cytosolic 
interdomain linkers.1 Great efforts over the past 7 years have shed light onto the structure of 
other voltage-gated sodium channels (mainly bacterial proteins)5, 6 and the first structure of an 
eukaryotic voltage-gated sodium channel α subunit has recently been solved.7 While these 
and other studies have provided invaluable insight into voltage-gating mechanisms and pore 
structure, the role and organisation of cytosolic domains is less clear. The linker between 
domains DI and DII (LDI-DII) of NaV1.5 contains 295 residues and has been of particular 
interest to us and other groups due to the fact that LDI-DII undergoes post-translational 
modifications including phosphorylation and arginine methylation (for a recent review see ref. 
8). Biochemical, genetic and electrophysiological studies suggest that LDI-DII participates in 
the regulation of channel inactivation.9 
Voltage-gated sodium channels have long been known to be regulated by proteases.10 
For example, calpain cleaves the brain isoform of the voltage-gated sodium channel, NaV1.2, 
at LDI-DII.11 Calpain sodium channel fragments interact and localise at the plasma membrane 
hours after calpain activation,11 suggesting that these fragments retain the protein–protein 
interactions that hold the sodium channel macromolecular complex together. However, there 
is currently no information on whether these fragments are subsequently degraded. A 
thought-provoking alternative is that sodium channel proteolysis creates new proteins with 
modified biological activities. In this addendum, we further our understanding of SCN5A 
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gene expression by showing that LDI-DII contains a nuclear localisation signal (NLS), localises 
to the cell nucleus when expressed as an isolated domain in cardiac-like H9c2 cells, and 
increases SCN5A promoter activity in vitro. 
 
Results 
LDI-DII is predicted to be a target for calpain and contains an NLS 
Previous reports have shown that LDI-DII from NaV1.2 is a target for calpain. We used two 
published protease site prediction algorithms to search for possible calpain cleavage sites in 
the NaV1.5 LDI-DII sequence (residues 416-711).12, 13 Both algorithms predicted calpain 
cleavage after position E462. The other common hot spots for calpain cleavage in LDI-DII were 
the regions spanning residues 512-524, 573-579, and 630-644 (Figure 1A). 
Inspection of the sodium channel LDI-DII sequences revealed the presence of a 
conserved arginine-rich motif including residues 474-481 (Figures 1A and 1B). We 
hypothesised that this motif could be a classical basic NLS. To test this hypothesis, we cloned 
the entire NaV1.5 LDI-DII as a FLAG-YFP fusion protein in a mammalian expression vector. 
We transfected this plasmid into H9c2 cells and observed LDI-DII expression mainly in the 
nucleus (Figure 2, left). When we mutated R474, R475, R478, R479 and R481 to K residues, 
the localisation of the linker was no longer restricted to cell nuclei (Figure 2, right). We 
repeated these transfections more than 10 times and reproducibly observed a similar 
fluorescence pattern. 
LDI-DII increases the activity of SCN5A promoter 
Why would an isolated cytosolic domain of a voltage-gated sodium channel localise to the 
cell nucleus? We asked whether LDI-DII could modify SCN5A expression. We transfected 
H9c2 cells with a plasmid expressing luciferase under the control of the SCN5A promoter 
(“promoter A” in the original publication),4 together with plasmids expressing either LDI-DII 
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with an intact NLS, or LDI-DII with a mutated NLS (R474, R475, R478, R479 and R481 to K 
as above). Our luciferase assays showed that LDI-DII with intact NLS, but not the mutated 
version, stimulated SCN5A promoter activity in a dose-dependent manner (Figure 3). 
Discussion 
In this addendum, we have built on our recently published investigation of SCN5A 
transcriptional regulation,4 to identify another possible mechanism controlling SCN5A gene 
expression i.e. LDI-DII stimulation of the SCN5A proximal promoter. We have identified an 
NLS in LDI-DII and provided evidence that nuclear LDI-DII enhances SCN5A transcription. 
These new results should be regarded as preliminary at this stage given the nature of our cell 
and in vitro studies, but they raise the exciting possibility that SCN5A expression may be 
regulated by sodium channel proteolysis. 
Proteolysis of sodium channel β subunits is known to regulate transcription of α 
subunits such as NaV1.1, the brain isoform of the voltage-gated sodium channel. The group of 
Kovacs, and others, demonstrated that 1) ADAM10 and BACE1 proteases cleave off the 
extracellular domain of the β2 subunit; 2) γ-secretase releases the β2 intracellular domain, 
and 3) the β2 intracellular domain is internalised into the cell nucleus (by unknown 
mechanisms) and induces an increase in NaV1.1 mRNA and protein levels.14, 15, 16 The β1 
subunit is also a target for BACE1 in vitro,16 and β1 silencing has recently been shown to 
result in decreased NaV1.1 mRNA (and protein) levels in cell models.17 
NLS often consist of short arginine-rich sequences, and have been described in 
voltage-gated potassium channels, notably KV10.1.18 We have found that NaV1.5 LDI-DII 
localises to the cell nucleus when expressed as an isolated domain in H9c2 cells, and that this 
nuclear localisation is abrogated by mutation of five R residues to K in the sequence 
RRSKRRKR spanning residues 474-481 of NaV1.5. To our knowledge, this is the first report 
of an NLS in α subunits of voltage-gated sodium channels. Sequence alignment suggests that 
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the NLS could be conserved among other members of the voltage-gated sodium channel 
family, including conservation of R474 and R475 in four and five members of the family, 
respectively, and an essential R478 (NaV1.5 numbering throughout, Figure 1B). Taking 
together our new observations with previous reports, it is tempting to speculate that calpain 
(alone or in combination with other proteases) cleavage of α subunits11, 19 creates LDI-DII 
fragments containing NLS, and that nuclear LDI-DII play a role in cardiac sodium channel 
transcriptional regulation, likely in combination with transcription factors.  
Our approach was limited by the lack of information on precise calpain proteolytic 
site(s) within LDI-DII. Both algorithms used here predicted cleavage after E462, and we 
identified 3 possible calpain sites C-terminal to the NLS. Given these uncertainties, we 
decided to clone the complete 295-residue long LDI-DII domain and not smaller LDI-DII 
fragments. Mapping both calpain sites on LDI-DII experimentally and identifying the required 
sequences in LDI-DII necessary for activation of SCN5A transcription would greatly help 
design further experiments to understand the relevance of our results in more physiological 
contexts. While acknowledging these weaknesses, this report raises the intriguing possibility 
that mutations and post-translational modifications of LDI-DII may control sodium channel 
activity not only at the electrophysiological level but also at the gene expression level. 
Bearing in mind that 1) the exact role of LDI-DII remains to be fully explored, 2) there are at 
least 63 disease-causing mutations in LDI-DII,20 and 3) there are 15-20 phosphorylation sites,21, 
22 as well as 3 arginine methylation sites (R513, R526 and R680)9 in LDI-DII, our findings 
provide a new lens to look at the involvement of LDI-DII in NaV1.5 currents and 
arrhythmogenic diseases.  
Methods 
Cells and plasmids 
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Cardiac cells derived from embryonic rat ventricle (H9c2 cells) were maintained under 
standard cell culture conditions. LDI-DII (residues 416-711) was amplified by PCR from a 
pCDNA3.1-based plasmid encoding for NaV1.5,9 and cloned as a FLAG-YFP fusion into 
pCDNA3.1.23 Site-directed mutagenesis was done using the Quikchange kit from Agilent 
Technologies, following the instructions of the manufacturer 
(http://www.genomics.agilent.com/en/Site-Directed-Mutagenesis/QuikChange-
Lightning/?cid=AG-PT-175&tabId=AG-PR-1162). Sanger sequencing was performed in-
house to ensure the introduction of the desired mutations. Cells were transfected using 
Lipofectamine 2000 (Thermo Fisher, 
https://www.thermofisher.com/uk/en/home/brands/product-
brand/lipofectamine/lipofectamine-2000.html) and analysed 24-48 h after transfection. 
Prediction of calpain sites in LDI-DII 
We used recently published algorithms to predict calpain sites in LDI-DII. The FASTA 
sequence of LDI-DII was analysed using the CaMPDB and GPS-CCD databases,12, 13 at score 
thresholds of 0.14 and 0.9, respectively. 
Confocal microscopy 
Cells were fixed (4% paraformaldehyde) and permeabilised in 1% Triton-X100. We used an 
anti-FLAG antibody to detect LDI-DII (Sigma, 
http://www.sigmaaldrich.com/catalog/product/sigma/f3165?lang=en&region=GB), as well as 
fluorescent phalloidin to mark F-actin (Thermo Fisher, 
https://www.thermofisher.com/order/catalog/product/A12379) and DAPI for nuclear staining. 
Cells were visualised by confocal microscopy in a Zeiss LSM 710. 
Reporter assays  
Luciferase / Renilla assays were performed as described in the original publication,4 using 
LDI-DII plasmids. Results from 4 biological replicates are reported here. 
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Western blot 
H9c2 cells were lysed in 1% NP-40 48 h after transfection. We used an anti-GFP antibody 
(Abcam, http://www.abcam.com/gfp-antibody-chip-grade-ab290.html) to detect LDI-DII-
FLAG-YFP expression. Two biological replicates were done. 
Acknowledgements 
DOO acknowledges Rivers state university of Science & Technology Port Harcourt Nigeria, 
and TETfund Nigeria (Academic staff Training and development unit) for funding. AT 
acknowledges a predoctoral fellowship from University of Girona (BR2012/47), MP-A a 
predoctoral fellowship from Generalitat de Catalunya (2014FI_B 00586). This work was 
supported by the University of Hull, the Spanish Government (SAF2011-27627) and 7PM-
PEOPLE Marie Curie International Reintegration Grant (PIRG07-GA-2010-268395). We 
thank Kath Bulmer for excellent technical assistance. 
Disclosure statement 
The authors have declared no conflict of interest. 
 
  
9 
 
References 
1 Gabelli SB, Yoder JB, Tomaselli GF, Amzel LM. Calmodulin and Ca(2+) control of 
voltage gated Na(+) channels. Channels (Austin). 2016;10(1):45-54. doi: 
10.1080/19336950.2015.1075677. 
2 Papadatos GA, Wallerstein PM, Head CE, Ratcliff R, Brady PA, et al. (2002) Slowed 
conduction and ventricular tachycardia after targeted disruption of the cardiac sodium 
channel gene Scn5a. Proc Natl Acad Sci USA 99: 6210–6215. 
3 Priest BT, McDermott JS. Cardiac ion channels. Channels (Austin). 2015;9(6):352-9. doi: 
10.1080/19336950.2015.1076597. 
4 Tarradas A, Pinsach-Abuin ML, Mackintosh C, Llorà-Batlle O, Pérez-Serra A, Batlle M, 
Pérez-Villa F, Zimmer T, Garcia-Bassets I, Brugada R, Beltran-Alvarez P, Pagans S. 
Transcriptional regulation of the sodium channel gene (SCN5A) by GATA4 in human heart. 
J Mol Cell Cardiol. 2017 Jan;102:74-82. doi:10.1016/j.yjmcc.2016.10.013. 
5 Payandeh J, Scheuer T, Zheng N, Catterall WA. The crystal structure of a voltage-gated 
sodium channel. Nature. 2011 Jul 10;475(7356):353-8. doi:10.1038/nature10238. 
6 Sula A, Booker J, Ng LC, Naylor CE, DeCaen PG, Wallace BA. The complete structure of 
an activated open sodium channel. Nat Commun. 2017 Feb 16;8:14205. doi: 
10.1038/ncomms14205. 
7 Shen H, Zhou Q, Pan X, Li Z, Wu J, Yan N. Structure of a eukaryotic voltage-gated sodium 
channel at near-atomic resolution. Science. 2017 Mar 3;355(6328). pii: eaal4326. doi: 
10.1126/science.aal4326. 
8 Onwuli DO, Beltran-Alvarez P. An update on transcriptional and post-translational 
regulation of brain voltage-gated sodium channels. Amino Acids. 2016 Mar;48(3):641-51. 
doi: 10.1007/s00726-015-2122-y. 
10 
 
9 Beltran-Alvarez P, Pagans S, Brugada R. The cardiac sodium channel is post-translationally 
modified by arginine methylation. J Proteome Res. 2011 Aug 5;10(8):3712-9. doi: 
10.1021/pr200339n. 
10 Paillart C, Boudier JL, Boudier JA, Rochat H, Couraud F, Dargent B. Activity-induced 
internalization and rapid degradation of sodium channels in cultured fetal neurons. J Cell Biol. 
1996 Jul;134(2):499-509. 
11 von Reyn CR, Mott RE, Siman R, Smith DH, Meaney DF. Mechanisms of calpain 
mediated proteolysis of voltage gated sodium channel α-subunits following in vitro dynamic 
stretch injury. J Neurochem. 2012 Jun;121(5):793-805. doi: 10.1111/j.1471-
4159.2012.07735.x.  
12 duVerle D, Takigawa I, Ono Y, Sorimachi H, Mamitsuka H. CaMPDB: a resource for 
calpain and modulatory proteolysis. Genome Inform. 2010 Jan;22:202-13. 
13 Liu Z, Cao J, Gao X, Ma Q, Ren J, Xue Y. GPS-CCD: a novel computational program for 
the prediction of calpain cleavage sites. PLoS One. 2011 Apr 20;6(4):e19001. 
14  Kim DY, Ingano LA, Carey BW, Pettingell WH, Kovacs DM. Presenilin/gamma-
secretase-mediated cleavage of the voltage-gated sodium channel beta2-subunit regulates cell 
adhesion and migration. J Biol Chem. 2005 Jun 17;280(24):23251-61. 
15 Kim DY, Carey BW, Wang H, Ingano LA, Binshtok AM, Wertz MH, Pettingell WH, He P, 
Lee VM, Woolf CJ, Kovacs DM. BACE1 regulates voltage-gated sodium channels and 
neuronal activity. Nat Cell Biol. 2007 Jul;9(7):755-64 
16 Wong HK, Sakurai T, Oyama F, Kaneko K, Wada K, Miyazaki H, Kurosawa M, De 
Strooper B, Saftig P, Nukina N. beta Subunits of voltage-gated sodium channels are novel 
substrates of beta-site amyloid precursor protein-cleaving enzyme (BACE1) and gamma-
secretase. J Biol Chem. 2005 Jun 17;280(24):23009-17. 
11 
 
17 Baroni D, Picco C, Barbieri R, Moran O. Antisense-mediated post-transcriptional silencing 
of SCN1B gene modulates sodium channel functional expression. Biol Cell. 2014 
Jan;106(1):13-29. doi: 10.1111/boc.201300040 
18 Chen Y, Sánchez A, Rubio ME, Kohl T, Pardo LA, Stühmer W. Functional K(v)10.1 
channels localize to the inner nuclear membrane. PLoS One. 2011 May3;6(5):e19257. doi: 
10.1371/journal.pone.0019257. 
19 von Reyn CR, Spaethling JM, Mesfin MN, Ma M, Neumar RW, Smith DH, Siman R, 
Meaney DF. Calpain mediates proteolysis of the voltage-gated sodium channel alpha-subunit. 
J Neurosci. 2009 Aug 19;29(33):10350-6. doi:10.1523/JNEUROSCI.2339-09.2009. 
20 Stenson, P. D.,Mort, M., Ball, E. V., Shaw, K. et al., The human gene mutation database: 
building a comprehensive mutation repository for clinical and molecular genetics, diagnostic 
testing and personalized genomic medicine. Hum. Genet. 2014, 133, 1–9. 
21 Baek JH, Rubinstein M, Scheuer T, Trimmer JS. Reciprocal changes in phosphorylation 
and methylation of mammalian brain sodium channels in response to seizures. J Biol Chem. 
2014 May 30;289(22):15363-73. doi:10.1074/jbc.M114.562785. 
22 Herren AW, Weber DM, Rigor RR, Margulies KB, Phinney BS, Bers DM. CaMKII 
Phosphorylation of Na(V)1.5: Novel in Vitro Sites Identified by Mass Spectrometry and 
Reduced S516 Phosphorylation in Human Heart Failure. J Proteome Res. 2015 May 
1;14(5):2298-311. doi: 10.1021/acs.jproteome.5b00107. 
23 Beltran-Alvarez P, Espejo A, Schmauder R, Beltran C, Mrowka R, Linke T, Batlle M, 
Pérez-Villa F, Pérez GJ, Scornik FS, Benndorf K, Pagans S, Zimmer T, Brugada R. Protein 
arginine methyl transferases-3 and -5 increase cell surface expression of cardiac sodium 
channel. FEBS Lett. 2013 Oct 1;587(19):3159-65. doi:10.1016/j.febslet.2013.07.043. 
  
12 
 
 
Legends 
Figure 1. A. Sequence of LDI-II (residues 416-711 of NaV1.5) highlighting predicted calpain 
cleavage sites (E462, and regions 512-524, 573-579, and 630-644) as well as the putative 
NLS (underlined). B. Sequence alignment of possible NLS in NaV members (NaV1.5 
numbering), highlighting conserved arginines (in black) and R residues 474, 475, 478, 479 
and 481 (underlined). 
Figure 2. Representative confocal microscopy images of H9c2 cells transfected with LDI-II 
including intact (left) and mutated (right) NLS. Scale bar corresponds to 50 µm.  
Figure 3. A. Luciferase experiments in H9c2 cells transfected with an SCN5A promoter-
luciferase construct and increasing amounts (447 and 895 ng) of the indicated pcDNA3.1-
based LDI-II expression plasmids encoding for LDI-II with intact and mutated NLS (residues 
474-481). Luciferase values were normalized to renilla and are shown as fold induction 
relative to non-overexpressing control conditions (mean ± SEM, n = 4). Significance was 
examined by the t-test relative to control: * p = 0.03, ** p = 0.001. B. Representative Western 
blot showing expression of LDI-II with intact and mutated NLS (895 ng plasmid each). 
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